Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
antibody-drug conjugates
Biotech
AstraZeneca-Daiichi lay down phase 1 breast cancer data for ADC
Chasing Gilead, results for the partners' TROP2-directed antibody-drug conjugate suggest they have a shot at coming from behind to disrupt the market.
Nick Paul Taylor
Dec 9, 2022 9:50am
NextCure, LegoChem join big-league rivals in ADC race
Nov 16, 2022 9:40am
Exelixis goes 3 in 3 with $30M for 3 Catalent programs
Nov 3, 2022 1:20pm
ESMO: Daiichi dazzles in lung cancer to dial up hopes for ADC
Sep 12, 2022 8:30am
Synaffix allies with Emergence in $360M biobuck ADC pact
Sep 6, 2022 8:50am
ImmunoGen delays pivotal top-line blood cancer data to 2024
Aug 31, 2022 8:40am
